primary%20biliary%20cholangitis
PRIMARY BILIARY CHOLANGITIS

Primary biliary cholangitis (formerly primary biliary cirrhosis) is a chronic, progressive, autoimmune, cholestatic liver disease more common in middle-aged women. It is characterized by destruction of small to medium bile ducts leading to cholestasis and frequently, end-stage liver disease.
Diagnostic features are chronic biochemical cholestasis, presence of antimitochondrial antibodies and the characteristic liver biopsy findings.


 

Introduction

  • Primary biliary cholangitis (PBC) is an autoimmune disease of a chronic and progressive nature, characterized by destruction of small to medium bile ducts, leading to cholestasis and frequently, end-stage liver disease
    • Diagnostic features of PBC are the chronic biochemical cholestasis, presence of antimitochondrial antibodies (AMA) and the characteristic liver biopsy findings
  • Suggested to have environmental and/or genetic factors affecting its development
  • PBC is more common in Northern Europeans and the majority of the patients are middle-aged women
    •  Men with the disease are more likely to develop hepatocellular carcinoma (HCC)

Signs and Symptoms

Fatigue

  • The most common symptom seen in 50-78% of patients
  • Associated with depression, obsessive-compulsive disorder and sleep disturbances
  • Symptom does not correlate with severity of liver disease

Pruritus

  • Prevalence rate is 20-70% in patients with PBC
  • A circadian rhythm may be noted with worse symptoms at night
  • May be so severe as to cause severe emotional disturbance
  • May be present even in patients with good liver function
  • Declines in severity with time from diagnosis

Jaundice

  • Present in 10-60% of patients due to cholestasis

Right Upper Quadrant Pain

  • Occurs in 8-17% of patients
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Gastroenterology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Roshini Claire Anthony, 12 Feb 2020

Children with inflammatory bowel disease (IBD) do not appear to have an elevated risk of lymphoma following treatment with anti-tumour necrosis factor (TNF) agents, according to a study presented at the recent Crohn’s and Colitis Congress 2020.

Jairia Dela Cruz, 4 days ago
A diet low in fat and high in fibre seems well tolerated in patients with ulcerative colitis, not contributing to increased inflammation while significantly increasing populations of Faecalibacterium prausnitzii, according to a study presented at the 2020 Crohn's & Colitis Congress.
Pearl Toh, 14 Feb 2020
Donor selection for faecal microbiota transplant (FMT) can make a difference to maintenance of long-term remission in patients with ulcerative colitis (UC), reveals a study presented at the 2020 Crohn's & Colitis Congress (CCC).
Stephen Padilla, 3 days ago
Use of proton pump inhibitors (PPIs) among patients with Crohn’s disease (CD) could increase their risk of interval flare and is associated with nonremission status, according to a study presented at the 2020 Crohn’s and Colitis Congress (CCC 2020).